A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
Phase of Trial: Phase IV
Latest Information Update: 07 Jul 2018
At a glance
- Drugs Cabozantinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms EXAMINER
- Sponsors Exelixis
- 25 Jan 2018 Planned End Date changed from 1 Mar 2018 to 31 Mar 2019.
- 25 Jan 2018 Planned primary completion date changed from 1 Sep 2017 to 30 Sep 2018.
- 27 Mar 2015 New source identified and integrated (European Clinical Trials Database record:2013-003402-40)